Deutsche Bank upgrades AstraZeneca stock rating to hold on trial results

Deutsche Bank upgraded AstraZeneca to Hold from Sell and raised its price target to £117 from £115 after the stock fell about 3% since its October 2025 downgrade and underperformed European large-cap peers by roughly 10% on an FX-adjusted basis. The upgrade reflects a more neutral risk-reward profile after a negative SERENA4 breast-cancer trial result and concerns over patent cliffs, while AstraZeneca also reported mixed clinical outcomes across oncology, respiratory and ATTR-CM programs. RBC separately initiated coverage at Outperform with a £145 target, citing longer-term growth potential despite recent trial setbacks.

Analysis

The relevant setup is not the rating change but the dispersion within AZN’s pipeline: a late-stage oncology miss removes an upside leg from an already event-heavy valuation, while respiratory and lung-cancer readouts preserve meaningful optionality. That pushes AZN toward a stock-specific execution story rather than a broad pharma-beta trade over the next 1-3 months. With long-end Treasury yields above 5%, premium-growth pharma multiples are especially vulnerable if management cannot offset pipeline disappointments with explicit revenue, launch-curve, or margin guidance.

AMGN is the cleaner relative beneficiary if its partnered assets translate into commercially differentiated labels, but the value attribution depends on economics that are not yet disclosed. The more non-obvious implication is for BMY: setbacks in competing breast-cancer approaches can modestly reduce near-term competitive pressure, yet this is insufficient to repair BMY’s broader post-LOE growth and capital-allocation discount. Avoid treating an analyst target revision as a fundamental catalyst; target changes typically follow, rather than lead, the underlying revision cycle.

The ATTR-CM failure should not automatically be read as bearish for ALNY. If the result reflects a drug-specific issue, ALNY’s incumbent clinical dataset and commercial position become more defensible; if it reflects diminished incremental benefit on top of stabilizers, the entire RNAi opportunity set faces a lower peak-sales ceiling. The key falsifier is comparative subgroup evidence in patients receiving background stabilizer therapy, plus any changes to ALNY’s patient-start, persistence, or peak-sales commentary over the next two reporting cycles.

Key Decisions for Investors

• Maintain AZN as neutral rather than add on the rating action; revisit a long only after management quantifies how remaining launch assets close the revenue gap from failed programs. A 1-3 month catalyst is the next guidance update; downgrade risk rises if consensus revenue or EPS estimates fall despite stable headline guidance.
• Express relative quality through long AMGN / short AZN in equal dollar amounts for 3-6 months, sized modestly. The trade works if partnered respiratory and oncology assets receive positive regulatory or commercial validation while AZN faces estimate cuts; stop if AZN raises medium-term revenue guidance or AMGN discloses immaterial economics or weak launch uptake.
• Put ALNY on an event-driven watchlist, not an immediate short. Buy only if forthcoming subgroup data demonstrate that the competing ATTR-CM failure is molecule-specific and ALNY maintains initiation and persistence trends; avoid or short a rally if evidence points to class-wide attenuation among stabilizer-treated patients.
• Use BMY as a funding short only against a more directly supported oncology long, not as a standalone read-through trade. The oncology competitive benefit is too narrow to alter BMY’s structural multiple unless it is accompanied by a broader improvement in franchise durability and post-patent-cliff guidance.